Method for amplification production of natural killer cells
By using pretreatment solution for closed amplification culture in the bioreactor, the problem of difficulty and low efficiency of natural killer cells is solved, and a large number of cells is efficiently acquired and the risk of contamination is reduced. It is suitable for clinical and tissue engineering applications.
Patent Information
- Application Number
- CN202411410962.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-10
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, the culture of natural killer cells is difficult and the amplification efficiency is low, resulting in large consumption of consumables and high labor costs. The probability of consumable culture at laboratory scale is high, making it difficult to meet the large-scale application in clinical and tissue engineering. need.
The first and second treatment solutions were prepared by centrifugation, filtration, concentration and freeze-drying of the blood samples and supernatant, and the cell purity was improved and cell purity was improved. Amplification efficiency promotes high-density reproduction and growth of natural killer cells.
It realizes the acquisition of a large number of natural killer cells in a short time, reduces the operating intensity and contamination risk, improves cell purity and amplification efficiency, and the second treatment solution can be used for subsequent amplification and the production of cytokine IFN-γ, and is used in Clinical Medicine.
Smart Images

Figure CN118995601A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of natural killer cell production, and in particular to a method for amplifying and producing natural killer cells. Background Art
[0002] Natural killer cells (NK cells) are important immune cells in the body. They are not only related to anti-tumor, anti-viral infection and immune regulation, but also participate in the occurrence of hypersensitivity reactions and autoimmune diseases in some cases. They can recognize target cells and kill mediators. NK cells have good application prospects in clinical and tissue engineering fields, and clinical and tissue engineering applications often require the use of large orders of magnitude (for example, 10 10 -10 11 Order of magnitude) of NK cells.
[0003] Since NK cells are difficult to cultivate, currently, NK cells are mainly produced by expansion culture in the laboratory using culture bottles, which not only leads to a large consumption of consumables such as culture bottles, but also has low production efficiency and high labor costs. In addition, the probability of contamination in laboratory-scale NK cell expansion culture is high. Summary of the invention
[0004] The purpose of the present application is to provide a method for amplifying and producing natural killer cells, which aims to improve the existing technical problem of low amplification efficiency in producing natural killer cells.
[0005] The present application provides a method for amplifying and producing natural killer cells, and the method for amplifying and producing natural killer cells includes: inoculating natural killer cells in a bioreactor for amplification culture, obtaining natural killer cells after amplification culture; and in the process of amplification culture, adding a pretreatment liquid into the bioreactor; the amplification culture is a closed culture. The pretreatment liquid is a first treatment liquid or / and a second treatment liquid. The preparation method of the first treatment liquid includes: mixing a blood sample and physiological saline and performing a first centrifugation at 1000-1200r / min; mixing the precipitate after the first centrifugation with physiological saline and incubating for 2-3 days; performing a second centrifugation at 1200-1400r / min for the incubated system; performing a first filtration, a first concentration and desalination, and a first freeze drying on the supernatant after the second centrifugation, and mixing the system after the first freeze drying with sterile water; wherein the blood sample is peripheral blood or umbilical cord blood. The preparation method of the second treatment liquid includes: performing a second filtration, a second concentration and desalination, and a second freeze drying on the supernatant in the amplification culture system in sequence, and mixing the system after the second freeze drying with sterile water.
[0006] The method for amplifying and producing natural killer cells provided in the present application can obtain a large number of natural killer cells in a short period of time, and has simple operation, low work intensity, high amplification efficiency, and flexible production scale; and the use of a specific first treatment liquid and / or a second treatment liquid during the amplification culture process can improve the purity of the natural killer cells obtained by amplification and production; in addition, the second treatment liquid obtained by subjecting the supernatant in the system after amplification and culture of the present application to a specific treatment can continue to be used for subsequent amplification and production of natural killer cells, which can save costs; in the second treatment liquid, the content of the cytokine IFN-γ is relatively abundant, and the second treatment liquid can be used to produce and obtain the cytokine IFN-γ, and the obtained cytokine IFN-γ can be used in clinical medicine as a drug precursor for the treatment of type 2 diabetes and a reagent for alleviating immune dysfunction in patients with type 2 diabetes, etc.
[0007] In an optional embodiment of the present application, the volume of the blood sample is 30-50 mL; or / and the time for the first centrifugation and the second centrifugation is each independently 4-6 min; or / and the pressure and temperature of the first filtration, the first concentration and desalination, the second filtration and the second concentration and desalination are each independently 0.3-0.6 MPa and 2-8°C; or / and the first filtration and the second filtration both use multiple filtrations with successively decreasing pore sizes, and the minimum pore size of the first filtration and the second filtration is 15-25 μm; or / and the temperature and time of the first freeze-drying and the second freeze-drying are each independently -40--60°C and 3-6 h.
[0008] In an optional embodiment of the present application, the blood sample contains penicillin-streptomycin, and the final concentration of penicillin-streptomycin in the blood sample is 80-120 U / mL.
[0009] In an optional embodiment of the present application, during the expansion culture process, a pretreatment solution is added to the bioreactor by a feeding method.
[0010] The above technical solution is conducive to avoiding the risk of contamination during the expansion and culture process, and can also improve the purity of natural killer cells obtained by expansion production.
[0011] Optionally, the pretreatment solution is added to the bioreactor in a multiple feeding manner.
[0012] Optionally, each time the feed is added, the volume of the pretreatment liquid added to the bioreactor is 25 to 35 mL; wherein, in the first treatment liquid, the volume ratio of the first freeze-dried system to sterile water is 1:(2 to 4); in the second treatment liquid, the volume ratio of the second freeze-dried system to sterile water is 1:(2 to 4).
[0013] In an optional embodiment of the present application, during the expansion culture process, an expansion culture medium is added into the bioreactor; the expansion culture medium contains autologous serum, gentamicin and basal culture medium.
[0014] The above technical solution can promote the reproduction and growth of natural killer cells.
[0015] Optionally, the method for preparing the amplification culture medium includes: mixing a basal culture medium and an autologous serum solution in a volume ratio of (15 to 25): (0.8 to 1.2); wherein the basal culture medium contains gentamicin, and the concentration of gentamicin in the basal culture medium is 600 to 1000 U / mL; and the mass fraction of the autologous serum in the autologous serum solution is 1 to 5%.
[0016] Optionally, the expansion culture medium is added to the bioreactor by means of fed-batch feeding.
[0017] Optionally, the expansion culture medium is added to the bioreactor by multiple feeding methods.
[0018] Optionally, expansion culture medium is added to the bioreactor on the 2nd to 4th day and the 5th to 7th day of expansion culture.
[0019] Optionally, the carbon source content of the feed is 0.5-5 g / L.
[0020] In an optional embodiment of the present application, the bioreactor is a BioFlo 110 bioreactor.
[0021] In an optional embodiment of the present application, the expansion culture time is 4 to 30 days.
[0022] The above technical solution is conducive to the high-density reproduction and growth of natural killer cells in the bioreactor.
[0023] In an optional embodiment of the present application, a method for obtaining natural killer cells inoculated in a bioreactor includes: inoculating a cell system containing an induction culture medium, mononuclear cells and a pretreatment solution into a culture bag for induction culture; wherein the mononuclear cells include peripheral blood mononuclear cells or umbilical cord blood mononuclear cells.
[0024] The above technical solution can induce culture to obtain natural killer cells to be inoculated in a bioreactor.
[0025] In an optional embodiment of the present application, the induction culture time is 2 to 7 days; or, the induction culture is terminated when the number of cells in the culture bag reaches 3 to 20 times the initial number of cells in the culture bag.
[0026] Optionally, the capacity of the culture bag is 500 to 2000 mL.
[0027] In an optional embodiment of the present application, the preparation method of the cell system includes: adding cell fluid and pretreatment fluid to the induction culture fluid. The cell density of mononuclear cells in the cell fluid is 1×10 6 ~1.5×10 6 In the first treatment solution, the volume ratio of the first freeze-dried system to sterile water is 1:(2-4); in the second treatment solution, the volume ratio of the second freeze-dried system to sterile water is 1:(2-4); and the volume ratio of the cell fluid to the pretreatment solution is (20-25):(1-2).
[0028] Optionally, the induction culture medium contains autologous serum, gentamicin and basal culture medium.
[0029] Optionally, the method for preparing the induction culture fluid includes: mixing a basal culture medium and an autologous serum solution in a volume ratio of (15 to 25): (0.8 to 1.2); wherein the basal culture medium contains gentamicin, and the concentration of gentamicin in the basal culture medium is 600 to 1000 U / mL; and the mass fraction of the autologous serum in the autologous serum solution is 1 to 5%. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.
[0031] Figure 1 This is a flow chart of the method for preparing the first treatment liquid provided in this application.
[0032] Figure 2 A flow chart of the method for amplifying and producing natural killer cells provided in this application.
[0033] Figure 3 This is a flow chart of the method for preparing the second processing liquid provided in this application.
[0034] Figure 4 This is a cell morphology diagram of natural killer cells obtained after amplification and production in Example 1 of the present application.
[0035] Figure 5 This is a comparison chart of the amplification changes of the methods for amplifying and producing natural killer cells provided in Examples 1 to 5 of the present application. DETAILED DESCRIPTION
[0036] The present application provides a method for amplifying and producing natural killer cells, which comprises: inoculating natural killer cells into a bioreactor for amplification culture to obtain the amplified natural killer cells; and during the amplification culture, adding a pretreatment solution into the bioreactor.
[0037] The pretreatment liquid is the first treatment liquid and / or the second treatment liquid.
[0038] The preparation method of the first treatment liquid includes: mixing a blood sample and physiological saline and performing a first centrifugation at 1000-1200 r / min; mixing the precipitate after the first centrifugation with physiological saline and incubating for 2-3 days; performing a second centrifugation at 1200-1400 r / min on the incubated system; performing a first filtration, a first concentration and desalination, and a first freeze-drying on the supernatant after the second centrifugation in sequence, and mixing the system after the first freeze-drying with sterile water; wherein the blood sample is peripheral blood or umbilical cord blood.
[0039] The method for preparing the second treatment liquid comprises: performing second filtration, second concentration and desalination, and second freeze drying on the supernatant in the system after amplification and culture, and mixing the system after the second freeze drying with sterile water.
[0040] It is understandable that, since the present application is a method for amplifying and producing natural killer cells, the equipment and the like involved in the process of amplifying and producing natural killer cells are all sterilized. The aforementioned "natural killer cells obtained after amplification and culture" are natural killer cells obtained by amplification and production. The aforementioned "supernatant in the system after amplification and culture" are the supernatant suspension in the bioreactor after amplification and culture.
[0041] The method for amplifying and producing natural killer cells provided in the present application can obtain a large number of natural killer cells in a short period of time, and has simple operation, low work intensity, high amplification efficiency, and flexible production scale. The closed culture in the bioreactor effectively avoids the risks of contamination during the amplification culture process. In addition, the use of a specific first treatment liquid or / and a second treatment liquid during the amplification culture process can not only improve the purity of the natural killer cells obtained by amplification production, but also help NK cells significantly reduce the risk and severity of graft-versus-host disease when administered allogeneically, and can also promote the amplification of natural killer cells.
[0042] The supernatant in the system after amplification and culture of the present application is subjected to specific treatment, and the obtained second treatment liquid can be continuously used for subsequent amplification and production of natural killer cells. When the natural killer cells are subsequently amplified and produced, the supernatant in the system after amplification and culture can be further treated to obtain the second treatment liquid for subsequent amplification and production of natural killer cells, that is, the supernatant in the system after amplification and culture as a by-product can be reused, forming a production cycle mechanism, which can save costs.
[0043] In addition, the content of cytokine IFN-γ in the second treatment liquid is relatively rich, and the second treatment liquid can be used to produce cytokine IFN-γ, and the obtained cytokine IFN-γ can be used in clinical medicine as a drug precursor for the treatment of type 2 diabetes and a reagent for alleviating immune dysfunction in patients with type 2 diabetes.
[0044] The following is a detailed description of the preparation method of the first treatment solution. Figure 1 For a flow chart of the preparation method of the first treatment solution provided in this application, please refer to Figure 1 The preparation method of the first treatment liquid provided in the present application comprises the following steps:
[0045] S110, obtaining a blood sample.
[0046] In the present application, the blood sample is peripheral blood or umbilical cord blood.
[0047] In some optional embodiments of the present application, the volume of the blood sample is 30 to 50 mL.
[0048] In some optional embodiments of the present application, the blood sample contains penicillin-streptomycin, and the final concentration of penicillin-streptomycin in the blood sample is 80-120 U / mL.
[0049] S120, mixing the blood sample and physiological saline and then performing a first centrifugation; mixing the precipitate after the first centrifugation and physiological saline and then incubating; and performing a second centrifugation on the incubated system.
[0050] In the present application, the rotation speed of the first centrifugation is 1000-1200 r / min.
[0051] In some optional embodiments of the present application, the first centrifugation time is 4 to 6 minutes.
[0052] As an example, 2 to 5 volumes of physiological saline are added to the blood sample, followed by a first centrifugation.
[0053] In the present application, the rotation speed of the second centrifugation is 1200-1400 r / min.
[0054] In some optional embodiments of the present application, the second centrifugation time is 4 to 6 minutes.
[0055] As an example, 2 to 5 volumes of physiological saline are added to the precipitate after the first centrifugation, and then the second centrifugation is performed.
[0056] In the present application, the incubation time is 2 to 3 days. As an example, the incubation is performed in a culture bottle, and the culture bottle is placed in an incubator at a temperature of 37° C. and a CO 2 concentration of 5% for incubation.
[0057] In other optional embodiments of the present application, the blood sample may be subjected to the first centrifugation, incubation and second centrifugation operations repeatedly 2 to 3 times.
[0058] S130, performing first filtration, first concentration and desalination, and first freeze-drying on the supernatant after the second centrifugation in sequence, and mixing the system after the first freeze-drying with sterile water.
[0059] In some optional embodiments of the present application, the pressure and temperature of the first filtration and the first concentration and desalination are independently 0.3-0.6 MPa and 2-8° C.
[0060] In some optional embodiments of the present application, the first filtration adopts multiple filtrations with successively decreasing pore sizes, and the minimum pore size of the first filtration is 15 to 25 μm.
[0061] As an example, the first filtering step includes: passing the supernatant after the second centrifugation through filters of 120 μm, 80 μm, 40 μm and 20 μm in sequence.
[0062] In some optional embodiments of the present application, the first concentration and desalination uses a filtration membrane with a molecular weight cutoff of 2 to 4 KD.
[0063] In some optional embodiments of the present application, the temperature and time of the first freeze-drying are -40 to -60°C and 3 to 6 hours, respectively.
[0064] As an example, the system after the first concentration and desalination is frozen to -50°C within 3 to 6 hours, and after vacuum drying, the temperature is raised to 2 to 8°C, and then the system after the first freeze-drying is mixed with sterile water.
[0065] In some optional embodiments of the present application, in the first treatment liquid, the volume ratio of the system after the first freeze-drying to sterile water (ie, sterile water) is 1:(2-4).
[0066] Figure 2 For a flow chart of the method for amplifying and producing natural killer cells provided in this application, please refer to Figure 2 The method for amplifying and producing natural killer cells provided in the present application comprises the following steps:
[0067] S210, obtaining natural killer cells to be inoculated.
[0068] In some optional embodiments of the present application, the method for obtaining natural killer cells inoculated in a bioreactor includes: inoculating a cell system containing an induction culture medium, mononuclear cells and a pretreatment solution into a culture bag for induction culture; wherein the mononuclear cells include peripheral blood mononuclear cells or umbilical cord blood mononuclear cells.
[0069] The above method can induce culture to obtain natural killer cells to be inoculated into the bioreactor.
[0070] As an example, peripheral blood mononuclear cells can be derived from fresh or frozen thawed peripheral blood, with a starting cell density of 1×10 6 ~5×10 6 / mL; Umbilical cord blood mononuclear cells can be derived from fresh or frozen thawed cord blood, with an initial cell density of 2×10 6 ~8×10 6 Pieces / mL.
[0071] In some optional embodiments of the present application, the induction culture time is 2 to 7 days; or, when the number of cells in the culture bag reaches 3 to 20 times the initial number of cells in the culture bag, the induction culture is terminated.
[0072] In some optional embodiments of the present application, the capacity of the culture bag is 500-2000 mL.
[0073] As an example, when the culture volume in the culture bag is less than half of the capacity of the culture bag, the culture bag needs to be folded before being placed for culture; and during induction culture, the cells need to be fully dispersed or larger cell clusters need to be rubbed open to observe with the naked eye according to the situation of the clone clusters.
[0074] In some optional embodiments of the present application, the preparation method of the cell system includes: adding cell solution and pretreatment solution to the induction culture solution. The cell density of mononuclear cells in the cell solution is 1×10 6 ~1.5×10 6 In the first treatment solution, the volume ratio of the first freeze-dried system to sterile water is 1:(2-4); in the second treatment solution, the volume ratio of the second freeze-dried system to sterile water is 1:(2-4); and the volume ratio of the cell fluid to the pretreatment solution is (20-25):(1-2).
[0075] As an example, 20 to 25 mL of cell solution and 1.5 mL of pretreatment solution were added to the induction culture solution.
[0076] Furthermore, the induction culture medium contains autologous serum, gentamicin and basal culture medium.
[0077] Furthermore, the method for preparing the induction culture fluid includes: mixing a basal culture medium and an autologous serum solution in a volume ratio of (15-25):(0.8-1.2); wherein the basal culture medium contains gentamicin, and the concentration of gentamicin in the basal culture medium is 600-1000U / mL; and the mass fraction of the autologous serum in the autologous serum solution is 1-5%.
[0078] As an example, the basal medium is Corning 581 serum-free medium.
[0079] In the present application, the aforementioned basic culture medium containing gentamicin needs to be stored at 4°C for future use.
[0080] It should be noted that in other feasible embodiments of the present application, natural killer cells in culture may be directly prepared into a cell suspension to serve as the natural killer cells to be inoculated.
[0081] S220, inoculating natural killer cells into a bioreactor for expansion culture to obtain natural killer cells after expansion culture; and during the expansion culture process, adding a pretreatment liquid into the bioreactor; the pretreatment liquid is the first treatment liquid and / or the second treatment liquid; the expansion culture is a closed culture.
[0082] It can be understood that the natural killer cells used for inoculation in the bioreactor in step S220 are the natural killer cells to be inoculated obtained in step S210.
[0083] In some optional embodiments of the present application, the natural killer cells to be inoculated obtained in step S210 can be directly inoculated into the bioreactor, or the natural killer cell system to be inoculated obtained in step S210 can be concentrated to 1 to 5 times the volume and then inoculated into the bioreactor.
[0084] In some optional embodiments of the present application, the bioreactor is a BioFlo 110 bioreactor.
[0085] In some optional embodiments of the present application, the expansion culture time is 4 to 30 days; this is conducive to the high-density reproduction and growth of natural killer cells in the bioreactor, and the purity of the natural killer cells obtained by the expansion production is relatively high. The supernatant in the system after the expansion culture is subjected to specific treatment and the cytokine IFN-γ content in the second treated liquid is relatively rich.
[0086] In the present application, the pretreatment liquid is the first treatment liquid and / or the second treatment liquid, and the pretreatment liquid is added to the bioreactor during the amplification culture process. The above method can improve the purity of the natural killer cells obtained by amplification production.
[0087] In some optional embodiments of the present application, during the expansion culture process, the pretreatment liquid is added to the bioreactor by feeding. The above method is conducive to avoiding the risk of contamination during the expansion culture process and can also improve the purity of the natural killer cells obtained by expansion production.
[0088] Furthermore, the pretreatment liquid is added into the bioreactor in a multiple feeding manner.
[0089] In some optional embodiments of the present application, each time the feed is added, the volume of the pretreatment liquid added to the bioreactor is 25-35 mL; wherein, in the first treatment liquid, the volume ratio of the first freeze-dried system to sterile water is 1:(2-4); in the second treatment liquid, the volume ratio of the second freeze-dried system to sterile water is 1:(2-4). The above method can improve the purity of the natural killer cells obtained by amplification production.
[0090] In some optional embodiments of the present application, during the expansion culture process, an expansion culture solution is added to the bioreactor; the expansion culture solution contains autologous serum, gentamicin and basal culture medium. The above method can promote the reproduction and growth of natural killer cells.
[0091] Furthermore, the preparation method of the amplification culture medium includes: mixing a basal culture medium and an autologous serum solution in a volume ratio of (15-25):(0.8-1.2); wherein the basal culture medium contains gentamicin, and the concentration of gentamicin in the basal culture medium is 600-1000U / mL; and the mass fraction of the autologous serum in the autologous serum solution is 1-5%.
[0092] In some optional embodiments of the present application, the expansion culture medium is added to the bioreactor by means of feeding.
[0093] Furthermore, the expansion culture medium is added into the bioreactor by multiple feeding methods.
[0094] In some optional embodiments of the present application, expansion culture medium is added to the bioreactor on the 2nd to 4th day and the 5th to 7th day of expansion culture.
[0095] As an example, expansion culture medium is added to the bioreactor on the 3rd and 7th days of expansion culture.
[0096] In some optional embodiments of the present application, the carbon source content of the feed is 0.5-5 g / L.
[0097] It should be noted that the shelf life of the amplification culture medium is short and it cannot be used more than one week after preparation; the storage temperature of the amplification culture medium is 4°C. Each time the amplification culture medium is added to the bioreactor, the amplification culture medium needs to be naturally rewarmed at room temperature and cannot be directly placed in a 37°C incubator to rewarm.
[0098] It is understandable that the natural killer cells obtained after expansion and culture can be used directly or frozen for later use.
[0099] Figure 3 For a flow chart of the preparation method of the second treatment liquid provided in this application, please refer to Figure 3The preparation method of the second treatment liquid provided in the present application comprises the following steps:
[0100] S310, performing a second filtration, a second concentration and desalting, and a second freeze-drying on the supernatant in the system after the amplification culture.
[0101] In some optional embodiments of the present application, the pressure and temperature of the second filtration and the second concentration and desalination are independently 0.3-0.6 MPa and 2-8° C.
[0102] In some optional embodiments of the present application, the second filtration adopts multiple filtrations with successively decreasing pore sizes, and the minimum pore size of the second filtration is 15 to 25 μm.
[0103] As an example, the second filtration step includes: passing the supernatant after the amplification culture through 120 μm, 80 μm, 40 μm and 20 μm filters in sequence.
[0104] In some optional embodiments of the present application, the second concentration and desalination uses a filtration membrane with a molecular weight cutoff of 2 to 4 KD.
[0105] In some optional embodiments of the present application, the temperature and time of the second freeze-drying are -40 to -60°C and 3 to 6 hours, respectively.
[0106] As an example, the second concentrated and desalted system is frozen to -50°C within 3 to 6 hours, vacuum dried, and then the temperature is raised to 2 to 8°C. The second freeze-dried system is then mixed with sterile water.
[0107] S320, mixing the second freeze-dried system with sterile water.
[0108] In some optional embodiments of the present application, in the second treatment liquid, the volume ratio of the second freeze-dried system to sterile water (i.e., sterile water) is 1:(2-4).
[0109] In order to make the purpose, technical scheme and advantages of the embodiments of the present application clearer, the technical scheme in the embodiments of the present application will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0110] Example 1
[0111] This embodiment provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0112] (1) Preparation of the first treatment solution:
[0113] Add 3 volumes of saline to the peripheral blood, centrifuge at 1000r / min for 5 minutes, and then take the precipitate. Then add 3 volumes of saline to the precipitate, mix well, and transfer to a culture bottle. Place the culture bottle in an incubator at 37°C and 5% CO2 for 3 days. Collect the incubated system, centrifuge at 1400r / min for 5 minutes, and take the supernatant suspension.
[0114] Under the conditions of 0.45MPa and 5°C, the above-mentioned supernatant suspension is sequentially passed through 120μm, 80μm, 40μm, and 20μm filters to obtain a filtrate; the filtrate is then concentrated and desalted using a filter membrane with a molecular weight cutoff of 3KD; the concentrated and desalted system is then frozen to -50°C within 6 hours, vacuum-dried, and then the temperature is raised to 5°C, and then added to 3 times the volume of sterilized water to dissolve, to obtain a first treated liquid.
[0115] (2) Expansion and production of natural killer cells:
[0116] Add 25 mL of cell culture medium with a cell density of 1×10 6 Peripheral blood mononuclear cells of 100 cells / mL and 1.5 mL of the first treatment solution are inoculated into a disposable culture bag for induced culture for 7 days. After the cell number in the disposable culture bag reaches 20 times the initial cell number, they are directly inoculated into a sterilized bioreactor for expansion culture. After 7 days of expansion culture, the natural killer cells amplified and produced in the bioreactor and the supernatant suspension in the bioreactor are obtained.
[0117] In the process of amplifying and culturing natural killer cells using a bioreactor, the bioreactor adopts a closed culture system, and on the 3rd and 7th days of the amplification culture, the system in the bioreactor is centrifuged to obtain cell precipitates, and then the obtained cell precipitates, 30 mL of amplification culture medium and 1.5 mL of the first treatment liquid are added to the bioreactor to continue the amplification culture.
[0118] The preparation method of the amplification culture medium is as follows: adding gentamicin with a final concentration of 800 U / mL to Corning 581 serum-free culture medium to prepare a basal culture medium; then mixing 20 mL of the basal culture medium and 1 mL of a 5% autologous serum solution to obtain an amplification culture medium.
[0119] (3) Preparation of the second treatment solution:
[0120] Under the conditions of 0.45 MPa and 5° C., the supernatant suspension in the bioreactor obtained in step (2) is passed through 120 μm, 80 μm, 40 μm, and 20 μm filters in sequence to obtain a filtrate; the filtrate is then concentrated and desalted using a filter membrane with a molecular weight cutoff of 3 KD; the concentrated and desalted system is then frozen to -50° C. within 6 hours, vacuum-dried, and then the temperature is raised to 5° C., and then added to 3 times the volume of sterilized water to dissolve, to obtain a second treated liquid.
[0121] Example 2
[0122] This embodiment provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0123] (1) Expansion and production of natural killer cells:
[0124] Add 25 mL of cell culture medium with a cell density of 1×10 6 Peripheral blood mononuclear cells of 1.5 mL / mL and 1.5 mL of the second treatment solution obtained in Example 1 were inoculated in a disposable culture bag for induced culture for 6 days. After the cell number in the disposable culture bag reached 20 times the starting cell number, they were directly inoculated in a sterilized bioreactor for expansion culture. After 6 days of expansion culture, the natural killer cells amplified and produced in the bioreactor and the supernatant suspension in the bioreactor were obtained.
[0125] In the process of amplifying and culturing natural killer cells using a bioreactor, the bioreactor adopts a closed culture system, and on the 3rd and 6th days of the amplification culture, the system in the bioreactor is centrifuged to obtain cell precipitates, and then the obtained cell precipitates, 30 mL of amplification culture medium and 1.5 mL of the first treatment liquid are added to the bioreactor to continue the amplification culture.
[0126] The preparation method of the amplification culture medium is as follows: adding gentamicin with a final concentration of 800 U / mL to Corning 581 serum-free culture medium to prepare a basal culture medium; then mixing 20 mL of the basal culture medium and 1 mL of a 4% autologous serum solution to obtain an amplification culture medium.
[0127] (2) Preparation of the second treatment solution:
[0128] Under the conditions of 0.45 MPa and 5° C., the supernatant suspension in the bioreactor obtained in step (1) is passed through 120 μm, 80 μm, 40 μm, and 20 μm filters in sequence to obtain a filtrate; the filtrate is then concentrated and desalted using a filter membrane with a molecular weight cutoff of 3 KD; the concentrated and desalted system is then frozen to -50° C. within 6 hours, vacuum-dried, and then the temperature is raised to 5° C., and then added to 3 times the volume of sterilized water to dissolve, to obtain a second treated liquid.
[0129] Experimental Example 3
[0130] This embodiment provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0131] (1) Expansion and production of natural killer cells:
[0132] Add 25 mL of cell culture medium with a cell density of 1×10 6 Peripheral blood mononuclear cells of 1.5 mL / mL and 1.5 mL of the second treatment solution obtained in Example 1 were inoculated in a disposable culture bag for induced culture for 5 days. After the cell number in the disposable culture bag reached 20 times the starting cell number, they were directly inoculated in a sterilized bioreactor for expansion culture. After 5 days of expansion culture, the natural killer cells amplified and produced in the bioreactor and the supernatant suspension in the bioreactor were obtained.
[0133] In the process of amplifying and culturing natural killer cells using a bioreactor, the bioreactor adopts a closed culture system, and on the 3rd and 5th days of the amplification culture, the system in the bioreactor is centrifuged to obtain cell precipitates, and then the obtained cell precipitates, 30 mL of amplification culture medium and 1.5 mL of the first treatment liquid are added to the bioreactor to continue the amplification culture.
[0134] The preparation method of the amplification culture medium is as follows: adding gentamicin with a final concentration of 800 U / mL to Corning 581 serum-free culture medium to prepare a basal culture medium; then mixing 20 mL of the basal culture medium and 1 mL of a 3% autologous serum solution to obtain an amplification culture medium.
[0135] (2) Preparation of the second treatment solution:
[0136] Under the conditions of 0.45 MPa and 5° C., the supernatant suspension in the bioreactor obtained in step (1) is passed through 120 μm, 80 μm, 40 μm, and 20 μm filters in sequence to obtain a filtrate; the filtrate is then concentrated and desalted using a filter membrane with a molecular weight cutoff of 3 KD; the concentrated and desalted system is then frozen to -50° C. within 6 hours, vacuum-dried, and then the temperature is raised to 5° C., and then added to 3 times the volume of sterilized water to dissolve, to obtain a second treated liquid.
[0137] Experimental Example 4
[0138] This embodiment provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0139] (1) Expansion and production of natural killer cells:
[0140] Add 25 mL of cell culture medium with a cell density of 1.5 × 10 6 Peripheral blood mononuclear cells of 1.5 mL / mL and 1.5 mL of the second treatment solution obtained in Example 1 were inoculated in a disposable culture bag for induced culture for 6 days. After the cell number in the disposable culture bag reached 20 times the starting cell number, they were directly inoculated in a sterilized bioreactor for expansion culture. After 6 days of expansion culture, the natural killer cells amplified and produced in the bioreactor and the supernatant suspension in the bioreactor were obtained.
[0141] In the process of amplifying and culturing natural killer cells using a bioreactor, the bioreactor adopts a closed culture system, and on the 3rd and 6th days of the amplification culture, the system in the bioreactor is centrifuged to obtain cell precipitates, and then the obtained cell precipitates, 30 mL of amplification culture medium and 1.5 mL of the first treatment liquid are added to the bioreactor to continue the amplification culture.
[0142] The preparation method of the amplification culture medium is as follows: adding gentamicin with a final concentration of 800 U / mL to Corning 581 serum-free culture medium to prepare a basal culture medium; then mixing 20 mL of the basal culture medium and 1 mL of a 4% autologous serum solution to obtain an amplification culture medium.
[0143] (2) Preparation of the second treatment solution:
[0144] Under the conditions of 0.45 MPa and 5° C., the supernatant suspension in the bioreactor obtained in step (1) is passed through 120 μm, 80 μm, 40 μm, and 20 μm filters in sequence to obtain a filtrate; the filtrate is then concentrated and desalted using a filter membrane with a molecular weight cutoff of 3 KD; the concentrated and desalted system is then frozen to -50° C. within 6 hours, vacuum-dried, and then the temperature is raised to 5° C., and then added to 3 times the volume of sterilized water to dissolve, to obtain a second treated liquid.
[0145] Experimental Example 5
[0146] This embodiment provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0147] (1) Expansion and production of natural killer cells:
[0148] Add 25 mL of cell culture medium with a cell density of 1.5 × 10 6Peripheral blood mononuclear cells of 1.5 mL / mL and 1.5 mL of the second treatment solution obtained in Example 1 were inoculated in a disposable culture bag for induced culture for 7 days. After the cell number in the disposable culture bag reached 20 times the starting cell number, they were directly inoculated in a sterilized bioreactor for expansion culture. After 7 days of expansion culture, the natural killer cells amplified and produced in the bioreactor and the supernatant suspension in the bioreactor were obtained.
[0149] In the process of amplifying and culturing natural killer cells using a bioreactor, the bioreactor adopts a closed culture system, and on the 3rd and 7th days of the amplification culture, the system in the bioreactor is centrifuged to obtain cell precipitates, and then the obtained cell precipitates, 30 mL of amplification culture medium and 1.5 mL of the first treatment liquid are added to the bioreactor to continue the amplification culture.
[0150] The preparation method of the amplification culture medium is as follows: adding gentamicin with a final concentration of 800 U / mL to Corning 581 serum-free culture medium to prepare a basal culture medium; then mixing 20 mL of the basal culture medium and 1 mL of a 5% autologous serum solution to obtain an amplification culture medium.
[0151] (2) Preparation of the second treatment solution:
[0152] Under the conditions of 0.45 MPa and 5° C., the supernatant suspension in the bioreactor obtained in step (1) is passed through 120 μm, 80 μm, 40 μm, and 20 μm filters in sequence to obtain a filtrate; the filtrate is then concentrated and desalted using a filter membrane with a molecular weight cutoff of 3 KD; the concentrated and desalted system is then frozen to -50° C. within 6 hours, vacuum-dried, and then the temperature is raised to 5° C., and then added to 3 times the volume of sterilized water to dissolve, to obtain a second treated liquid.
[0153] Comparative Example 1
[0154] This comparative example provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0155] Add 25 mL of cell culture medium with a cell density of 1×10 6 Peripheral blood mononuclear cells with a concentration of 1.5 mL / mL and IL-2 (interleukin-2) solution with a concentration of 200 U / mL were inoculated into a T75 square flask for expansion culture. After 7 days of expansion culture, the natural killer cells expanded and produced in the T75 square flask and the supernatant suspension in the T75 square flask were obtained.
[0156] On the 3rd and 7th days of the expansion culture, the system in the T75 square bottle was centrifuged to obtain the cell pellet, and then the obtained cell pellet, 30 mL of expansion culture medium and 1.5 mL of natural killer cell activation solution (purchased from Tianjin Haoyang Biological Products Technology Co., Ltd., model number TBDNK2013-S) were added to the T75 square bottle to continue the expansion culture.
[0157] The preparation method of the amplification culture medium is as follows: IL-2 with a final concentration of 200 U / mL and gentamicin with a final concentration of 800 U / mL are added to Corning 581 serum-free culture medium to prepare a basal culture medium; then 20 mL of the basal culture medium and 1 mL of a 5% autologous serum solution are mixed to obtain an amplification culture medium.
[0158] Comparative Example 2
[0159] This comparative example provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0160] Add 25 mL of cell culture medium with a cell density of 1×10 6 Peripheral blood mononuclear cells with a concentration of 1.5 mL / mL and IL-2 (interleukin-2) solution with a concentration of 200 U / mL were inoculated into a T75 square flask for expansion culture. After 6 days of expansion culture, the natural killer cells expanded and produced in the T75 square flask and the supernatant suspension in the T75 square flask were obtained.
[0161] On the 3rd and 6th days of the expansion culture, the system in the T75 square bottle was centrifuged to obtain the cell pellet, and then the obtained cell pellet, 30 mL of expansion culture medium and 1.5 mL of natural killer cell activation solution (purchased from Tianjin Haoyang Biological Products Technology Co., Ltd., model number TBDNK2013-S) were added to the T75 square bottle to continue the expansion culture.
[0162] The preparation method of the amplification culture medium is as follows: IL-2 with a final concentration of 200 U / mL and gentamicin with a final concentration of 800 U / mL are added to Corning 581 serum-free culture medium to prepare a basal culture medium; then 20 mL of the basal culture medium and 1 mL of a 4% autologous serum solution are mixed to obtain an amplification culture medium.
[0163] Comparative Example 3
[0164] This comparative example provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0165] Add 25 mL of cell culture medium with a cell density of 1×10 6Peripheral blood mononuclear cells with a concentration of 1.5 mL / mL and IL-2 (interleukin-2) solution with a concentration of 200 U / mL were inoculated into a T75 square flask for expansion culture. After 5 days of expansion culture, the natural killer cells expanded and produced in the T75 square flask and the supernatant suspension in the T75 square flask were obtained.
[0166] On the 3rd and 5th days of the expansion culture, the system in the T75 square bottle was centrifuged to obtain the cell pellet, and then the obtained cell pellet, 30 mL of expansion culture medium and 1.5 mL of natural killer cell activation solution (purchased from Tianjin Haoyang Biological Products Technology Co., Ltd., model number TBDNK2013-S) were added to the T75 square bottle to continue the expansion culture.
[0167] The preparation method of the amplification culture medium is as follows: IL-2 with a final concentration of 200 U / mL and gentamicin with a final concentration of 800 U / mL are added to Corning 581 serum-free culture medium to prepare a basal culture medium; then 20 mL of the basal culture medium and 1 mL of a 5% autologous serum solution are mixed to obtain an amplification culture medium.
[0168] Comparative Example 4
[0169] This comparative example provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0170] Add 25 mL of cell culture medium with a cell density of 1.5 × 10 6 Peripheral blood mononuclear cells with a concentration of 1.5 mL / mL and IL-2 (interleukin-2) solution with a concentration of 200 U / mL were inoculated into a T75 square flask for expansion culture. After 6 days of expansion culture, the natural killer cells expanded and produced in the T75 square flask and the supernatant suspension in the T75 square flask were obtained.
[0171] On the 3rd and 6th days of the expansion culture, the system in the T75 square bottle was centrifuged to obtain the cell pellet, and then the obtained cell pellet, 30 mL of expansion culture medium and 1.5 mL of natural killer cell activation solution (purchased from Tianjin Haoyang Biological Products Technology Co., Ltd., model number TBDNK2013-S) were added to the T75 square bottle to continue the expansion culture.
[0172] The preparation method of the amplification culture medium is as follows: IL-2 with a final concentration of 200 U / mL and gentamicin with a final concentration of 800 U / mL are added to Corning 581 serum-free culture medium to prepare a basal culture medium; then 20 mL of the basal culture medium and 1 mL of a 4% autologous serum solution are mixed to obtain an amplification culture medium.
[0173] Comparative Example 5
[0174] This comparative example provides a method for amplifying and producing natural killer cells, which comprises the following steps:
[0175] Add 25 mL of cell culture medium with a cell density of 1.5 × 10 6 Peripheral blood mononuclear cells with a concentration of 1.5 mL / mL and IL-2 (interleukin-2) solution with a concentration of 200 U / mL were inoculated into a T75 square flask for expansion culture. After 7 days of expansion culture, the natural killer cells expanded and produced in the T75 square flask and the supernatant suspension in the T75 square flask were obtained.
[0176] On the 3rd and 7th days of the expansion culture, the system in the T75 square bottle was centrifuged to obtain the cell pellet, and then the obtained cell pellet, 30 mL of expansion culture medium and 1.5 mL of natural killer cell activation solution (purchased from Tianjin Haoyang Biological Products Technology Co., Ltd., model number TBDNK2013-S) were added to the T75 square bottle to continue the expansion culture.
[0177] The preparation method of the amplification culture medium is as follows: IL-2 with a final concentration of 200 U / mL and gentamicin with a final concentration of 800 U / mL are added to Corning 581 serum-free culture medium to prepare a basal culture medium; then 20 mL of the basal culture medium and 1 mL of a 5% autologous serum solution are mixed to obtain an amplification culture medium.
[0178] Experimental Example 1
[0179] The natural killer cells obtained by amplification production in Example 1 were photographed, and the results are as follows: Figure 4 shown.
[0180] from Figure 4 It can be seen that the natural killer cells obtained by amplification and production in Example 1 have good morphology, which is a typical natural killer cell morphology.
[0181] Experimental Example 2
[0182] The natural killer cells were cultured according to the method for amplifying and producing natural killer cells provided in Examples 1 to 5, and the time of the amplification culture in step (2) was adjusted to 14 days. The amplification changes of the total cell amount of the natural killer cells were tested respectively. The results are as follows: Figure 5 shown.
[0183] Figure 5 In the examples, samples 1 to 5 correspond to the methods for amplifying and producing natural killer cells provided in Examples 1 to 5, respectively.
[0184] from Figure 5It can be seen that samples 1 to 5 all exhibit good amplification efficiency, indicating that the methods for amplifying and producing natural killer cells provided in Examples 1 to 5 have high amplification efficiency.
[0185] Experimental Example 3
[0186] The content of cytokine IFN-γ in the second treatment solution prepared in Examples 1 to 5 was tested and statistically analyzed, and the results are shown in Table 1.
[0187] Table 1
[0188] IFN-γ (pg / mL) Example 1 590.73 Example 2 588.51 Example 3 593.17 Example 4 592.48 Example 5 591.46
[0189] As can be seen from Table 1, the second treatment solutions prepared in Examples 1 to 5 contain a relatively rich expression of the cytokine IFN-γ, and have a good application prospect.
[0190] Experimental Example 4
[0191] The purity of the immune cells in the cell system obtained after amplification and production in Examples 1 to 5 was tested, and the test results are shown in Table 2.
[0192] Table 2
[0193] NK cell purity (%) T cell purity (%) CIK cell purity (%) Example 1 91.2 1.4 4.2 Example 2 90.7 1.6 4.3 Example 3 91.6 1.5 4.1 Example 4 91.0 1.4 4.2 Example 5 91.1 1.3 4.2 Comparative Example 1 79.3 10.6 2.9 Comparative Example 2 77.1 9.9 2.8 Comparative Example 3 77.8 10.8 3.0 Comparative Example 4 80.6 9.4 2.9 Comparative Example 5 79.7 11.3 2.9
[0194] It can be seen from Table 2 that the purity of the natural killer cells amplified and produced by Examples 1-5 of the present invention is above 90%, while the purity of the natural killer cells amplified and produced by Comparative Examples 1-5 is far less than that of Examples 1-5.
[0195] In summary, the method for amplifying and producing natural killer cells of the present application can obtain a large number of natural killer cells in a short time, and has simple operation, low work intensity, high amplification efficiency, and flexible production scale; the use of a pretreatment liquid can improve the purity of the natural killer cells obtained by amplification and production; the second treatment liquid can continue to be used for subsequent amplification and production of natural killer cells, which can save costs; and the content of the cytokine IFN-γ in the second treatment liquid is relatively rich, and can be applied to clinical medicine.
[0196] The embodiments described above are part of the embodiments of the present application, rather than all of the embodiments. The detailed description of the embodiments of the present application is not intended to limit the scope of the present application for protection, but merely represents the selected embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present application.
Claims
1. A method for amplifying and producing natural killer cells, characterized in that: include: Inoculating the natural killer cells into a bioreactor for expansion and culture, and obtaining the natural killer cells after the expansion and culture; and during the amplification culture, adding a pretreatment solution into the bioreactor; The amplification culture is a closed culture; The pretreatment liquid is a first treatment liquid and / or a second treatment liquid; The preparation method of the first treatment liquid comprises: mixing a blood sample and physiological saline and performing a first centrifugation at 1000-1200 r / min; mixing the precipitate after the first centrifugation with physiological saline and incubating for 2-3 days; performing a second centrifugation at 1200-1400 r / min on the incubated system; performing a first filtration, a first concentration and desalination, and a first freeze-drying on the supernatant after the second centrifugation in sequence, and mixing the system after the first freeze-drying with sterile water; wherein the blood sample is peripheral blood or umbilical cord blood; The method for preparing the second treatment liquid comprises: sequentially performing second filtration, second concentration and desalination, and second freeze drying on the supernatant in the system after the amplification culture, and mixing the system after the second freeze drying with sterile water.
2. The method for amplifying and producing natural killer cells according to claim 1, characterized in that: The volume of the blood sample is 30-50 mL; Or / and, the time of the first centrifugation and the second centrifugation are each independently 4 to 6 minutes; or / and, the pressure and temperature of the first filtration, the first concentration and desalination, the second filtration and the second concentration and desalination are independently 0.3-0.6 MPa and 2-8° C.; Or / and, the first filtration and the second filtration are both performed by multiple filtrations with successively decreasing pore sizes, and the minimum pore sizes of the first filtration and the second filtration are 15 to 25 μm; Or / and, the temperature and time of the first freeze-drying and the second freeze-drying are independently -40 to -60°C and 3 to 6 hours.
3. The method for amplifying and producing natural killer cells according to claim 1, characterized in that: The blood sample contains penicillin-streptomycin, and the final concentration of penicillin-streptomycin in the blood sample is 80-120 U / mL.
4. The method for amplifying and producing natural killer cells according to claim 1, characterized in that: During the amplification culture, the pretreatment solution is added into the bioreactor by means of feeding; Optionally, the pretreatment solution is added into the bioreactor by multiple feeding methods; Optionally, each time the feed is added, the volume of the pretreatment liquid added to the bioreactor is 25 to 35 mL; wherein, in the first treatment liquid, the volume ratio of the first freeze-dried system to the sterile water is 1:(2 to 4); in the second treatment liquid, the volume ratio of the second freeze-dried system to the sterile water is 1:(2 to 4).
5. The method for amplifying and producing natural killer cells according to any one of claims 1 to 4, characterized in that: During the amplification culture process, adding an amplification culture solution into the bioreactor; the amplification culture solution contains autologous serum, gentamicin and basal culture medium; Optionally, the method for preparing the amplification culture medium comprises: mixing a basal culture medium and an autologous serum solution in a volume ratio of (15-25):(0.8-1.2); wherein the basal culture medium contains gentamicin, and the concentration of gentamicin in the basal culture medium is 600-1000 U / mL; and the mass fraction of the autologous serum in the autologous serum solution is 1-5%; Optionally, the expansion culture solution is added into the bioreactor by means of fed-batch feeding; Optionally, the expansion culture fluid is added into the bioreactor by multiple feeding methods; Optionally, the amplification culture solution is added into the bioreactor on the 2nd to 4th day and the 5th to 7th day of the amplification culture; Optionally, the carbon source content of the feed is 0.5-5 g / L.
6. The method for amplifying and producing natural killer cells according to any one of claims 1 to 4, characterized in that: The bioreactor is a BioFlo 110 bioreactor.
7. The method for amplifying and producing natural killer cells according to any one of claims 1 to 4, characterized in that: The amplification culture time is 4 to 30 days.
8. The method for amplifying and producing natural killer cells according to any one of claims 1 to 4, characterized in that: The method for obtaining the natural killer cells inoculated in the bioreactor comprises: inoculating a cell system containing an induction culture solution, mononuclear cells and the pretreatment solution into a culture bag for induction culture; Wherein, the mononuclear cells include peripheral blood mononuclear cells or umbilical cord blood mononuclear cells.
9. The method for amplifying and producing natural killer cells according to claim 8, characterized in that: The induction culture time is 2 to 7 days; Or, when the number of cells in the culture bag reaches 3 to 20 times the initial number of cells in the culture bag, the induction culture is terminated; Optionally, the capacity of the culture bag is 500 to 2000 mL.
10. The method for amplifying and producing natural killer cells according to claim 8, characterized in that: The preparation method of the cell system comprises: adding cell fluid and the pretreatment fluid to the induction culture fluid; The cell density of the mononuclear cells in the cell fluid is 1×10 6 ~1.5×10 6 Pieces / mL; In the first treatment liquid, the volume ratio of the first freeze-dried system to the sterile water is 1:(2-4); in the second treatment liquid, the volume ratio of the second freeze-dried system to the sterile water is 1:(2-4); and the volume ratio of the cell fluid to the pretreatment liquid is (20-25):(1-2); Optionally, the induction culture solution contains autologous serum, gentamicin and basal culture medium; Optionally, the method for preparing the induction culture fluid comprises: mixing a basal culture medium and an autologous serum solution in a volume ratio of (15-25):(0.8-1.2); wherein the basal culture medium contains the gentamicin, and the concentration of the gentamicin in the basal culture medium is 600-1000U / mL; and the mass fraction of the autologous serum in the autologous serum solution is 1-5%.
